15
Participants
Start Date
January 23, 2023
Primary Completion Date
May 22, 2024
Study Completion Date
May 22, 2024
Modakafusp Alfa
Modakafusp alfa intravenous infusion
Daratumumab
Daratumumab SC injection
Concord Repatriation General Hospital, Concord
The Alfred Hospital, Melbourne
New York Cancer and Blood Specialists, Bay Shore
Stony Brook University Hospital, Stony Brook
Institut Paoli-Calmettes, Marseille
Fundacion Instituto de Estudios Ciencias de la Salud de Castilla y Leon-Investigacion Biomedica de Salamanca (IBSAL), Salamanca
University of Cincinnati - Vontz Center for Molecular Studies, Cincinnati
Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
Chonnam National University Hwasun Hospital, Hwasun
CHRU Lille, Lille
Washington University School of Medicine, St Louis
HCA Midwest Health (Midwest Ventures Group HCA MidAmerica Division), Overland Park
University of Nebraska Medical Center, Omaha
Tulane University Health Sciences Center, New Orleans
Cedars-Sinai Medical Center, Los Angeles
Tranquil Clinical Research, Webster
Banner MD Anderson Cancer Center, Gilbert
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin
Zhejiang University School of Medicine - The First Affiliated Hospital (Zhejiang Provincial First Hospital), Hangzhou
Wuhan Union Hospital, Wuhan
Sun Yat-Sen University Cancer Center, Guangzhou
Floating Hospital for Children at Tufts Medical Center, Boston
Summit Medical Group PA, Florham Park
Centre Hospitalier Universitaire De Sherbrooke (CHUS) - Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont, Sherbrooke
Samsung Medical Center, Seoul
The Catholic University of Korea, Seoul St. Marys Hospital, Seoul
Hospital Universitario Vall d'Hebron, Barcelona
Lead Sponsor
Takeda
INDUSTRY